share_log

Keybanc Initiates Coverage On Standard BioTools With Overweight Rating, Announces Price Target of $4

Keybanc Initiates Coverage On Standard BioTools With Overweight Rating, Announces Price Target of $4

Keybanc以增持評級開始對標準BioTools進行保險,宣佈目標股價爲4美元
Benzinga ·  2023/07/12 01:29

Keybanc analyst Paul Knight initiates coverage on Standard BioTools (NASDAQ:LAB) with a Overweight rating and announces Price Target of $4.

KeyBanc分析師保羅·奈特在標準生物工具(納斯達克:LAB)上發起增持評級,並宣佈目標價為4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論